In the current real‐world study, therefore, we compared the OS and PFS of patients with EGFR‐mutant advanced NSCLC treated with the irreversible EGFR‐TKI afatinib or with one of two reversible EGFR‐TKIs, erlotinib or gefitinib, while also conducting a subgroup analysis among patients without BM. Here, EGFR is linked to non-small cell lung carcinoma.